Adults With Atopic Dermatitis at Increased Risk Of Venous Thromboembolism

Written By :  Dr. Kamal Kant Kohli
Published On 2023-06-07 04:15 GMT   |   Update On 2023-06-07 11:45 GMT

A recent study published in JAMA Dermatology has shed light on the potential link between atopic dermatitis (AD) and an elevated risk of developing venous thromboembolism (VTE) in adulthood. AD, a chronic inflammatory skin condition, has been previously associated with various cardiovascular comorbidities due to its systemic inflammatory effects. To investigate this further, a...

Login or Register to read the full article

A recent study published in JAMA Dermatology has shed light on the potential link between atopic dermatitis (AD) and an elevated risk of developing venous thromboembolism (VTE) in adulthood. AD, a chronic inflammatory skin condition, has been previously associated with various cardiovascular comorbidities due to its systemic inflammatory effects. To investigate this further, a comprehensive population-based cohort study was conducted.

This population-based nationwide cohort study was conducted by Tai-Li Chen and colleagues which aimed to assess the risk of developing venous thromboembolism (VTE) among patients with atopic dermatitis (AD). The study included adults aged 20 years or older who were newly diagnosed with AD between 2003 and 2017, along with matched controls. The data were obtained from the National Health Insurance Research Database. Patients with AD were further categorized based on the severity of the disease. The primary objective was to estimate hazard ratios (HRs) using a Cox regression model to evaluate the association between AD and incident VTE. Stratified analyses based on age and sex, as well as a sensitivity analysis excluding individuals using systemic steroids, were conducted.

The findings of the study were:

● The study analyzed a nationwide cohort of participants, comprising both individuals with AD and matched controls.

● A total of 284,858 participants were included, with an equal number of individuals in the AD cohort and the non-AD cohort.

● During the follow-up period, 0.7% of patients in the AD cohort (1066 individuals) and 0.6% in the non-AD cohort (829 individuals) developed VTE.

● The incidence rates were calculated at 1.05 and 0.82 per 1000 person-years, respectively.

● The results showed that adults with AD had a significantly higher risk of incident VTE compared to those without AD, with a hazard ratio (HR) of 1.28 (95% CI: 1.17-1.40).

● Subsequent analyses revealed that AD was associated with increased risks of deep vein thrombosis (HR: 1.26; 95% CI: 1.14-1.40) and pulmonary embolism (HR: 1.30; 95% CI: 1.08-1.57).

While the absolute risk difference of VTE between adults with and without AD appeared relatively small, the findings emphasize the importance of considering cardiovascular evaluation and necessary management for adults with AD who present symptoms suggestive of VTE.

This comprehensive cohort study provides evidence of an increased risk of developing venous thromboembolism among adults with atopic dermatitis. The findings highlight the importance of considering cardiovascular evaluation and appropriate management for individuals with AD who exhibit symptoms suggestive of VTE. Future research should focus on elucidating the underlying mechanisms linking AD and VTE to enhance our understanding of this association and improve patient care.

Reference:

Chen, T.-L., Huang, W.-T., Loh, C.-H., Huang, H.-K., & Chi, C.-C. (2023). Risk of venous thromboembolism among adults with atopic dermatitis. JAMA Dermatology (Chicago, Ill.). https://doi.org/10.1001/jamadermatol.2023.1300.

Tags:    
Article Source : JAMA Dermatology

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News